



MAYNE PHARMA TO PRESENT AT THE H.C. WAINWRIGHT 26TH ANNUAL GLOBAL INVESTMENT CONFERENCE

10 September 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O'Brien, Chief Executive Officer of Mayne Pharma, will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York City as follows:

Date: Tuesday, 10 September 2024

Time: 4:30pm US Eastern Time (Wednesday, 11 September 2024 at 6.30am AEST)

Webcast: [Click here](#)

A copy of the presentation slides is attached.

For further information contact:

Australia:

Dr Tom Duthy

+61 402 493 727

ir@maynepharma.com

US:

Lisa M. Wilson

+1 917-543-9932

ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](https://www.maynepharma.com).



Mayne Pharma Group Limited MYX.ASX

HC Wainwright Conference
September 10, 2024

Shawn Patrick O'Brien (CEO)
Aaron Gray (CFO)

Addressing
the needs
of patients



Disclaimer

The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company's audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.

Non-IFRS information

- Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to period.
- Earnings before interest, tax, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the operating earnings and performance of the Group and this information may be useful for investors as it provides additional and relevant information that reflects the underlying performance of the business.
- The non-IFRS financial information has not been audited by the Group's auditors.

Forward looking statements

- This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as 'potential', 'expect', 'anticipate', 'intend', 'plan' and 'may', and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company's continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company's future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company's ability to protect its intellectual property.

Other

- A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investor-relations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
- DORYX®, FABIOR®, KAPANOL®, LEXETTE®, SORILUX® and RHOFAD® are trademarks of Mayne Pharma. ACCUTANE®, ANNOVERA®, BETADINE®, BIJUVA®, IMVEXXY®, KADIAN®, NEXTSTELLIS®, ORACEA®, SOOLANTRA®, UROREC® and WYNZORA® and are trademarks of third parties.

Achieved all Key Operating Metrics in FY24¹

Deliver positive direct contribution in all three segments



- Strong revenue growth in Women's Health and Dermatology
- Achieved positive direct contribution² in all three segments in FY24:
 - Women's Health **\$35.2m**
 - Dermatology **\$44.3m**
 - International **\$9.0m**

Return Company to positive underlying EBITDA³ in FY24



- Positive underlying EBITDA of **\$22.9m** achieved in FY24
- Significant improvement on underlying EBITDA loss of (\$95.3m) in FY23

Optimise cost base with reductions of >US\$10m



- Direct opex as % revenue improved: 68.2% in FY23 to **33.5%** in FY24
- Cost containment measures executed in FY24 to right-size cost base
- Investments required for scientific studies and volume-based costs for growth

NEXTSTELLIS® run rate breakeven



- Achieved breakeven run rate from December 2023
- Positive contribution from NEXTSTELLIS® in 2HFY24
- Demand cycle⁴ growth **+85%** vs FY23

Return Company to positive operating cash generation in FY24



- **+\$8.1m** operating cash flow from continuing operations in FY24⁵
- Positive cash flow in 2HFY24

1. All numbers are expressed in AUD/A\$ terms unless otherwise stated.

2. Direct contribution calculated as gross margin less direct opex.

3. Underlying EBITDA is a non-IFRS measure and excludes earn-out reassessments, restructuring charges, class action settlement costs, derivative fair value adjustments and litigation expense.

4. Demand cycles calculated as IQVIA reported TRx (converted to units/cycles) plus non-reporting pharmacies (including Mayne Pharma's own distribution channel).

5. Total net operating cashflow (continued + discontinued operations) for FY24 was an outflow of \$15.3m, a reduction of 64% compared with FY23.

FY24 Financial Highlights¹

Simplification of our business model combined with our strong operating and financial discipline has delivered significantly improved financial results

\$388m

Revenue
up 112% FY23

56.3%

Gross margin
up from 45.5% FY23

\$22.9m

Underlying EBITDA²
up from (\$95.3m) FY23

\$88.5m

Segment contribution
up from (\$41.8m) FY23

\$8.1m

Operating cashflow from
continuing operations³
up from (\$51.5m) FY23

\$149.3m

Cash and marketable
securities at 30 June 2024
down from \$220.1m FY23

1. All numbers are expressed in AUD/A\$ terms unless otherwise stated.

2. Underlying EBITDA is a non-IFRS measure and excludes earn-out reassessments, restructuring charges, class action settlement costs, derivative fair value adjustments and litigation expense.

3. Total net operating cashflow (continued + discontinued operations) for FY24 was an outflow of \$15.3m, a reduction of 64% compared with FY23.

FY24 Operating Highlights

Women's Health



- 3 new US FDA Orange-Book listed NEXTSTELLIS® patents expiring 2036
- NEXTSTELLIS® achieved breakeven run rate from December and delivered positive contribution in 2HFY24
- 85% growth in demand cycles¹ for NEXTSTELLIS®, compared to FY23
- 31% growth in demand TRx² from licensed portfolio: ANNOVERA®, IMVEXXY® and BIJUVA®

Dermatology



- Completed asset purchase agreement to acquire the global rights to RHOFADÉ® from Novan, Inc. and EPI Health, LLC.
- New product launches driving growth – RHOFADÉ®, WYNZORA®, SOOLANTRA®, gACCUTANE® and authorised generic (AG) ORACEA®
- Channel strategy validated, moving to scale
- Shift towards products with more favourable gross to net profile

International



- Growth of NEXTSTELLIS®, oxycodone and UROREC® in Australia
- Modernisation project progressing well: new encapsulator in commercial production, enabling launch of KAPANOL® 200mg in FY24
- Increased demand for KADIAN® /KAPANOL® in Canada and Europe and expansion with business partners in other overseas territories
- Salisbury facility demonstrated significant positive step change in key operational metrics in a sustainable manner

1. Demand cycles calculated as IQVIA reported TRx (converted to units/cycles) plus non-reporting pharmacies (including Mayne Pharma's own distribution channel). TRx converted to units by taking number of pills in the TRx divided by 28 (number of NEXTSTELLIS® pills included in 1 month of therapy).

2. TRx – total prescriptions. For the period up to 31 December 2022 (prior to Mayne Pharma's purchase of license from TXMD), the data captures unadjusted IQVIA data only. For the period from 1 January 2023 (when Mayne Pharma started selling the products), the data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma's own distribution channel).

A thin, light gray diagonal line extending from the left edge of the slide towards the center.

FY24 Group Financial Performance

A decorative graphic in the bottom right corner consisting of several overlapping triangles in various shades of red, creating a geometric pattern.

Group Continuing Operations Overview¹: Improved operational performance

A\$ million ²	FY23	FY24	Change vs FY23 (\$)	Change vs FY23 (%)
Reported Revenue	183.6	388.4	204.8	112%
Reported Gross Profit	83.5	218.8	135.3	162%
Reported Direct Contribution	(41.8)	88.5	130.3	312%
Reported EBITDA	(102.0)	(92.5)	9.5	9%
Underlying EBITDA ³	(95.3)	22.9	118.2	124%
Reported Net Loss After Tax	(317.4)	(168.6)	148.8	47%
Operating Cash Flow Continuing Ops	(51.5)	8.1	59.6	116%

- Group Revenue of **\$388.4m** reflects growth from:
 - Women's Health, attributable to volume growth across the portfolio and full year impact of ANNOVERA®, IMVEXXY® and BIJUVA®
 - Dermatology, attributable to significantly improved core product profitability and new product launches of RHOFADÉ®, WYNZORA®, SOOLANTRA®, gACCUTANE® and AG ORACEA®
- Underlying EBITDA of **\$22.9m**, a **\$118.2m** improvement on FY23

1. Results are presented from continuing operations to exclude Metrics Contract Services (MCS) which was divested on 4 October 2022 and to exclude the US Retail Generics business (previously included in the Portfolio Products (PPD) segment) which was divested on 7 April 2023. The results include adjustments to all FY23 results, so they are presented on a comparable basis.


2. Attributable to members. EBITDA excludes asset impairments.

3. Underlying EBITDA excludes \$82.7m of earn-out reassessments, \$0.9m restructuring charges, \$33.2m class action settlement costs, (\$2.8m) derivative fair value adjustments, and \$1.3m litigation expense.


Improved cost leverage through growth and opex discipline (A\$m)

Segment Performance ¹ (A\$ million)	FY23	FY24	Change vs FY23
Revenue	183.6	388.4	112%
Gross Profit	83.5	218.8	162%
Direct Operating Expenses	(125.3)	(130.2)	4%
Direct Contribution	(41.8)	88.5	312%


Significant Operating Cost Leverage (A\$m) in FY24 vs. FY23



Revenue up 112% (+\$204.8m)



Direct opex up 4% (+\$4.9m)



Direct Contribution up 312% (+\$130.3m)

FY24 Commentary

- Cost containment measures executed in FY24 offset by certain increases:
 - Certain variable costs associated with revenue growth, such as samples and distribution costs
 - R&D, Medical and Regulatory Affairs increased costs due to required studies and investment in medical education to increase scientific awareness of the advantages of our products
- Reduced cost profile against expanded product portfolio, improving cost leverage (opex divided by revenue)
- Admin & Other expenses and Employee costs were flat on the pcg with the FX impact (total A\$4.7m) and on a constant currency, they declined 2% on the pcg
- Direct opex as % of revenue improved (33.5% in FY24 v 68.2% in FY23)

1. Refer Note 2 of the financial statements for additional detail on segment performance.

2. Refer P&L statement and Note 4 of the financial statements for additional detail on opex. Admin and Other excludes litigation/class action settlement, amortisation, share-based payments, restructuring, doubtful debts and convertible note derivative charges.

A thin, light gray diagonal line extending from the left edge of the slide towards the top right.


Segment Performance



Material Improvement in FY24 Direct Contribution¹

Benefit of scale and leverage starting to be demonstrated


FY23 Total Direct Contribution



+\$130.3m

\$88.5m

FY24 Total Direct Contribution



1. Direct contribution calculated as gross margin less direct opex.

Segment Performance

Refocused business delivering improved momentum and positive direct contribution in FY24

Reported results (A\$million)	2HFY23	1HFY24	2HFY24	FY23	FY24	Change vs FY23		2HFY23	1HFY24	2HFY24	FY23	FY24	Change vs FY23
<u>Revenue</u>							<u>Gross profit¹</u>						
Dermatology	45.8	80.9	93.9	57.0	174.9	207%	Dermatology	15.2	36.6	47.3	10.7	83.9	684%
Women's Health	48.5	72.4	70.4	61.9	142.8	131%	Women's Health	43.2	58.7	54.8	53.9	113.5	111%
International	37.1	34.6	36.1	64.7	70.7	9%	International	10.0	10.5	10.9	18.9	21.3	13%
Total	131.4	187.9	200.5	183.6	388.4	112%	Total	68.4	105.8	113.0	83.5	218.8	162%
<u>Operating expenses²</u>							<u>Direct Contribution</u>						
Dermatology	13.7	18.5	21.1	31.6	39.6	26%	Dermatology	1.5	18.1	26.2	(21.0)	44.3	311%
Women's Health	44.9	40.6	37.6	81.6	78.2	(4%)	Women's Health	-1.7	18.1	17.2	(27.7)	35.2	227%
International	6.0	6.1	6.3	12.1	12.4	3%	International	4.1	4.4	4.6	6.9	9.0	31%
Total	64.6	65.2	65.0	125.3	130.2	4%	Total	3.9	40.6	48.0	(41.8)	88.5	312%

1. Gross Profit includes FY24 depreciation of \$4.6m, which is included in COGS.

2. Direct opex includes FY24 lease depreciation of \$3.0m, which is largely related to motor vehicles of salesforce.



Women's Health

Women's Health – favourable macro trends positions Mayne Pharma well

Key macro trends in Women's Health

Mayne Pharma



Growing addressable Women's Health market

- Global menopause market hit US\$15.4bn in 2021 and is **projected to reach US\$24.4bn by 2030¹**
- Increased need for contraception options post *Roe v Wade* in the US

- BIJUVA® – **only** available, FDA approved bioidentical combination treatment for vasomotor symptoms associated with menopause
- NEXTSTELLIS® and ANNOVERA® are unique contraceptive solutions



Increased awareness and education

- Greater emphasis on **education and training** (Obs/Gyn) (historically, lack of clinical education in menopause – only 31% of Obs/Gyn report receiving menopause curriculum during residency)²
- Increased awareness of the impact of menopause (e.g. published articles, celebrities drawing awareness)

- Investment in Medical Science Liaisons to raise product scientific awareness
- Supporting education programs on the use of hormones for contraception and menopause
- Sales team of 85 able to reach target customers



Government Support / Initiatives

- **Affordable Care Act** - In all 50 states, the ACA guarantees coverage of women's preventive services for individuals and covered dependents
- **3 executive orders** by President Biden on strengthening access to contraception
- **Biden's US\$2bn** investment in Women's Health research & education

- Participate in efforts to provide information and feedback to lawmakers on ACA
- Working to develop programs that will benefit from the US\$2bn Women's Health program

1. <https://www.grandviewresearch.com/press-release/global-menopause-market>

2. Allen JT et al, 2023, Menopause. 1;30(10):1002-1005.



Women's Health: Strong NEXTSTELLIS® growth & full year impact of licensed portfolio

Women's Health in US\$'000	2HFY23	1HFY24	2HFY24	FY23	FY24
Total Revenue	32,667	47,277	46,361	41,671	93,638
Total Gross Profit	29,096	38,334	36,049	36,279	74,383
<i>Total Gross Profit % of Revenue</i>	89%	81%	78%	87%	79%
Direct OPEX	(30,310)	(26,527)	(24,765)	(54,921)	(51,292)
Direct Contribution*	(1,215)	11,807	11,284	(18,642)	23,091
Depreciation Add-Back	643	579	654	990	1,232
Earn-out liability	(1,877)	(3,422)	(3,561)	(1,877)	(6,983)
"Cash" Contribution**	(2,449)	8,964	8,377	(19,529)	17,341

FY24 Commentary

- FY24 revenue up US\$52m (125%) compared to FY23
- Revenue increase (FY23 to FY24) driven by:
 - Improved sales performance of NEXTSTELLIS®, as a result of refreshed sales leadership and marketing strategies
 - Volume growth of all key Women's Health products (NEXTSTELLIS®, ANNOVERA®, IMVEXXY® and BIJUVA®)
 - Full year impact of ANNOVERA®, IMVEXXY® and BIJUVA® (first six-month contribution from these products was in 2HFY23)
- Direct opex decreases in each half of FY24 vs 2HFY23 driven by territory optimisation and realigned marketing spend
- Main driver to lowering 2HFY24 revenue associated with legacy ANNOVERA® channel inventory expiration and returns (US\$7.2m revenue impact) – minimised risk of recurrence moving forward
- 2HFY24 TRx¹ growth for ANNOVERA® was +15% on 1HFY24 reflective of underlying growing demand

Segment details are shown in AUD terms in the Appendix

* Direct contribution calculated as gross profit less direct opex – includes depreciation of motor vehicle leases in direct opex


** Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability : portion of earnout liability related to revenues for the period independent of timing / capitalised amount

1. TRx – total prescriptions. For the period up to 31 December 2022 (prior to Mayne Pharma's purchase of license from TXMD), the data captures unadjusted IQVIA data only. For the period from 1 January 2023 (when Mayne Pharma started selling the products), the data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma's own distribution channel).

Women's Health: revenue, margin and contribution summary


■ NEXTSTELLIS® ■ ANNOVERA® ■ IMVEXXY® ■ BIJUVA® ■ OTHER

2HFY23 Total Revenue US\$32.7m




 Gross Margin: **89%**
 Direct opex: **US\$30.3m**
 Direct Cont.: **(US\$1.2m) / (A\$1.7m)**

1HFY24 Total Revenue US\$47.3m
+44.6% v 2HFY23



 Gross Margin: **81%**
 Direct opex: **US\$26.5m**
 Direct Cont.: **US\$11.8m / A\$18.1m**

2HFY24 Total Revenue US\$46.4m
+41.9% v pcp, -2% seq.




 Gross Margin: **78%**
 Direct opex: **US\$24.8m**
 Direct Cont.: **US\$11.3m / A\$17.1m**

NEXTSTELLIS® demand cycles¹ up 85%



NEXTSTELLIS® Quarterly US Demand Cycles (thousands)




FY24 Commentary

- Demand cycle growth of 85% on the pcp
- Strong Q4FY24 performance attributable to first full quarter with new leadership and improved salesforce execution



NEXTSTELLIS® Net Sales (US\$m) and growth (pcp)



FY24 Commentary

- 113% net sales growth for NEXTSTELLIS® in US market
- Net Selling Price (NSP) holding steady with continued volume growth


1. Demand cycles calculated as IQVIA reported TRx (converted to units/cycles) plus non-reporting pharmacies (including Mayne Pharma's own distribution channel). TRx converted to units by taking number of pills in the TRx divided by 28 (number of NEXTSTELLIS® pills included in 1 month of therapy). NEXTSTELLIS® prescriptions can be prescribed in 1-month and 3-month increments. On average 1 TRx equals 1.9 units/cycles.



Driving demand with IMVEXXY and BIJUVA for menopausal patients



Licensed Portfolio Demand TRx (thousands)¹



1. TRx – total prescriptions. For the period up to 31 December 2022 (prior to Mayne Pharma's purchase of license from TXMD), the data captures unadjusted IQVIA data only. For the period from 1 January 2023 (when Mayne Pharma started selling the products), the data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma's own distribution channel).



Dermatology

Dermatology:

Mayne Pharma can fill 1 in 3 retail Rx for med-derm¹

Key Macro trends in Dermatology



Mayne Pharma



Expanding treatable population

- Rising incidence of skin diseases, and a growing awareness and increased spend on personal care (e.g. Acne – **50m** people in the US)²
- Patient preference for consultation with specialist dermatologists for chronic skin conditions supports continued growth

- Increasing number of patients are treatable via Mayne Pharma's portfolio
- Portfolio of branded (DORYX®, FABIOR®, LEXETTE®, RHOFADÉ®, SORILUX® and WYNZORA®) and generic (n=20) gives focus and presence to dermatology writers



Retreat by Big Pharma from medical dermatology

- Few products in development for the treatment of common dermatology conditions, introducing a longer life cycle for currently available dermatology products

- Opportunity to expand our portfolio offering in near term via capital light transactions



Disintermediation

- Health insurance benefit design has shifted large cost burden to patients in dermatology
- Large retailers often carry limited dermatologic agents due to high costs and often call back prescribers to switch patients' prescriptions to older, cheaper options

- Leverage existing 400+ speciality pharmacies, convenient for repeat prescriptions across brands and generics
- Uninsured patients receive the prescribed product at a reasonable and predictable cost with limited special assistance from their dermatologist required

Dermatology:

Delivering on new product launches and channel strategy

Dermatology in US\$'000	2HFY23	1HFY24	2HFY24	FY23	FY24
Total Revenue	30,878	52,855	61,782	38,373	114,637
Total Gross Profit	10,226	23,908	31,119	7,191	55,028
<i>Total Gross Profit % of Revenue</i>	33%	45%	50%	19%	48%
Direct OPEX	(9,269)	(12,085)	(13,895)	(21,303)	(25,980)
Direct Contribution*	957	11,823	17,224	(14,112)	29,047
Depreciation Add-Back	(998)	581	600	863	1,181
Earn-out liability	-	(602)	(37)	(1,509)	(639)
"Cash" Contribution**	(41)	11,802	17,787	(11,740)	29,589

FY24 Commentary

- FY24 revenue up US\$76.3m (199%) compared to FY23
- Revenue increase (FY23 to FY24) driven by:
 - RHOFADE® sales following acquisition from Novan, Inc. and EPI Health, LLC in September 2023
 - additional new product launches, including gACCUTANE®, SOOLANTRA® and WYNZORA®
 - full year of sales of AG ORACEA®
- Co-pay costs across the portfolio improved in FY24 on a per-unit basis compared to FY23 with mix shifting towards products with more favourable gross-to-net profiles


Segment details are shown in AUD terms in the Appendix

* Direct contribution calculated as gross margin less direct opex – includes depreciation and allocation of shared functions & overhead within COGS and depreciation of motor vehicle leases in direct opex

** Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability: portion of earnout liability related to revenues for the period independent of timing / capitalised amount

Strong revenue, margin and contribution growth in Dermatology

FY23 Revenue by Category – TOTAL US\$38.4 million




Total Growth: 199%

Growth Drivers

RHOFADE® gACCUTANE® AG ORACEA®

FY24 Revenue by Category – TOTAL US\$114.6 million



Gross margin: **19%**



Direct opex: **US\$21.3m**



Direct contribution: **(US\$14.1m) / (A\$21.0m)**



Gross margin: **48%**



Direct opex: **US\$26.0m**



Direct contribution: **US\$29.0m / A\$44.3m**

Dermatology – channel strategy / full disintermediation


Network Ecosystem

Mayne Pharma is leveraging the inefficiencies in the dermatology value chain through new partnerships aimed at improving patient coverage, co-pay, inventory management, pharmacy stickiness and higher patient switching costs



Disintermediation

Involves removing the intermediary (wholesaler) between the manufacturer (Mayne Pharma) and the speciality pharmacy – excellent growth in FY24



Benefits of Mayne Pharma channel strategy

- Less burden for prescribers
- Ease of access for patients
- Ability to determine patient out of pocket cost and most economic location to get the prescription
- Improve ability to repeat prescriptions for chronic skin conditions
- Able to generate profit from a cash only dermatology prescription



International

International: Strategic and operational levers building momentum

International in A\$'000	2HFY23	1HFY24	2HFY24	FY23	FY24
Reported Revenue	37,079	34,608	36,105	64,704	70,713
Reported Gross Profit	10,048	10,480	10,902	18,924	21,382
<i>Total Gross Profit % of Revenue</i>	27%	30%	30%	29%	30%
Direct OPEX	(5,998)	(6,057)	(6,319)	(12,050)	(12,376)
Direct Contribution*	4,050	4,423	4,583	6,874	9,006
Depreciation Add-Back	1,983	1,943	1,862	4,146	3,805
Earn-out liability	-	(82)	-	(808)	(82)
"Cash" Contribution**	6,033	6,284	6,445	10,213	12,729

FY24 Commentary

- FY24 revenue up \$6m (9%) compared to FY23
- Revenue increase (FY23 to FY24) driven by:
 - growth of NEXTSTELLIS® (163% increase on FY23) in Australia
 - growth of oxycodone and UROREC® in Australia
 - increased demand for KAPANOL®/KADIAN® in European and Canadian markets
- Modernisation project progressing well: new encapsulator in commercial production, enabling launch of KAPANOL® 200mg in FY24
- Increased demand for KADIAN® /KAPANOL® in Canada and Europe and expansion with business partners in other overseas territories
- Partnered with Sandoz for distribution of oxycodone and metaraminol in Australia
- Salisbury facility demonstrated significant positive step change in key operational metrics in a sustainable manner

* Direct contribution calculated as gross margin less direct opex – includes depreciation and allocation of shared functions & overhead. Corresponds to 4D segment note

** Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability: portion of earnout liability related to revenues for the period independent of timing / capitalised amount

A thin, light gray diagonal line extending from the left edge of the slide towards the top right.

Outlook



FY25 outlook and focus

The Company expects to improve shareholder value with growth in underlying EBITDA in FY25 via revenue growth and cost leverage, with all three segments contributing positive direct contribution

Women's Health



Deliver profit potential of current Women's Health asset portfolio

- Drive growth through sharpened focus on sales execution and targeted marketing to deliver improved direct contribution
- Continue to raise product scientific awareness via Medical Science Liaisons and Key Opinion Leaders
- Further operating leverage to accelerate EBITDA growth

Dermatology



Differentiate channel solution to enable preferred solution for patients, prescribers and partners

- Continue to evaluate capital efficient and accretive business arrangements to further drive growth in revenue and margin
- Ensure channel strategy processes are easy to use
- Continuous development of channel strategy, leveraging ability to drive market share, access and financial performance

International



Drive International profit via new revenue streams and continuation of modernisation

- Leverage capacity created by operational improvements to grow and further operating leverage
- Complete modernisation upgrade program at the Salisbury facility to improve productivity and capabilities
- Continue to drive specialty and generic product sales, including driving growth in NEXTSTELLIS® in Australia

Q&A

For further information contact:

Australia:

Dr Tom Duthy

+61 402 493 727

ir@maynepharma.com

US:

Lisa M. Wilson

+1 917-543-9932

ir@maynepharma.com

You deserve tomorrow.